{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T13:57:32Z","timestamp":1694699852933},"reference-count":35,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Proceedings"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.transproceed.2017.12.012","type":"journal-article","created":{"date-parts":[[2018,2,3]],"date-time":"2018-02-03T00:36:24Z","timestamp":1517618184000},"page":"222-225","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Development of Duodenal Ulcers due to the Discontinuation of Proton Pump Inhibitors After the Induction of Sofosbuvir Plus Ledipasvir Therapy: A Report of Two Cases"],"prefix":"10.1016","volume":"50","author":[{"given":"S.","family":"Miuma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Miyaaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Miyazoe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Suehiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Taura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Nakao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.transproceed.2017.12.012_bib1","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0168-8278(00)80231-7","article-title":"HCV-related fibrosis progression following liver transplantation: increase in recent years","volume":"32","author":"Berenguer","year":"2000","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.transproceed.2017.12.012_bib2","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1053\/jhep.2002.33993","article-title":"Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients","volume":"36","author":"Berenguer","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.transproceed.2017.12.012_bib3","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/nature04083","article-title":"Hepatitis C and liver transplantation","volume":"436","author":"Brown","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.transproceed.2017.12.012_bib4","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.cld.2012.09.013","article-title":"Management of the transplant recipient with chronic hepatitis C","volume":"17","author":"Burton","year":"2013","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.transproceed.2017.12.012_bib5","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jhep.2008.05.002","article-title":"Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin","volume":"49","author":"Berenguer","year":"2008","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.transproceed.2017.12.012_bib6","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1111\/j.1600-6143.2008.02362.x","article-title":"Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection","volume":"8","author":"Veldt","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2017.12.012_bib7","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1097\/MCG.0b013e31819f66e2","article-title":"Long-term outcomes after treatment with interferon and ribavirin in HCV patients","volume":"43","author":"Aronsohn","year":"2009","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.transproceed.2017.12.012_bib8","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.jhep.2012.04.022","article-title":"Treatment of recurrent HCV infection following liver transplantation: results of a multicenter, randomized, versus placebo, trial of ribavirin alone as maintenance therapy after one year of PegIFNalpha-2a plus ribavirin","volume":"57","author":"Calmus","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.transproceed.2017.12.012_bib9","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1053\/j.gastro.2016.08.004","article-title":"Effectiveness of ledipasvir-sofosbuvir combination in patients with hepatitis C virus infection and factors associated with sustained virologic response","volume":"151","author":"Terrault","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.transproceed.2017.12.012_bib10","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1002\/hep.28571","article-title":"Hepatitis C disease burden in the United States in the era of oral direct-acting antivirals","volume":"64","author":"Chhatwal","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.transproceed.2017.12.012_bib11","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1016\/j.cgh.2015.07.015","article-title":"Hepatitis C virus treatment: is it possible to cure all hepatitis C virus patients?","volume":"13","author":"Muir","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.transproceed.2017.12.012_bib12","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/lt.24080","article-title":"Treatment of hepatitis C in liver transplant patients: interferon out, direct antiviral combos in","volume":"21","author":"Price","year":"2015","journal-title":"Liver Transpl"},{"key":"10.1016\/j.transproceed.2017.12.012_bib13","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/hep.28446","article-title":"Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence","volume":"63","author":"Poordad","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.transproceed.2017.12.012_bib14","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1111\/ajt.12714","article-title":"Directly acting antivirals (DAAs) for the treatment of chronic hepatitis C virus infection in liver transplant patients: \u201ca flood of opportunity\u201d","volume":"14","author":"Gane","year":"2014","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2017.12.012_bib15","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1056\/NEJMoa1408921","article-title":"An interferon-free antiviral regimen for HCV after liver transplantation","volume":"371","author":"Kwo","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.transproceed.2017.12.012_bib16","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1111\/ajt.13320","article-title":"Cost-effectiveness of new direct-acting antivirals to prevent post-liver transplant recurrent hepatitis","volume":"15","author":"Cortesi","year":"2015","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2017.12.012_bib17","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1007\/s00535-017-1310-9","article-title":"Treatment with sofosbuvir and ledipasvir without ribavirin for 12 weeks is highly effective for recurrent hepatitis C virus genotype 1b infection after living donor liver transplantation: a Japanese multicenter experience","volume":"52","author":"Ueda","year":"2017","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1016\/j.transproceed.2017.12.012_bib18","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/MCG.0000000000000640","article-title":"Use of sofosbuvir-based treatment of chronic hepatitis C in liver transplant recipients on hemodialysis","volume":"51","author":"Saab","year":"2017","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.transproceed.2017.12.012_bib19","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1097\/TP.0000000000001467","article-title":"Sofosbuvir\/ledipasvir without ribavirin achieved high sustained virologic response for hepatitis C recurrence after liver transplantation: two-center experience","volume":"101","author":"Elfeki","year":"2017","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2017.12.012_bib20","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/MOT.0000000000000198","article-title":"New hepatitis C virus therapies: drug classes and metabolism, drug interactions relevant in the transplant settings, drug options in decompensated cirrhosis, and drug options in end-stage renal disease","volume":"20","author":"Kwo","year":"2015","journal-title":"Curr Opin Organ Transplant"},{"key":"10.1016\/j.transproceed.2017.12.012_bib21","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/cid\/civ973","article-title":"Drug-drug interactions with novel all oral interferon-free antiviral agents in a large real-world cohort","volume":"62","author":"Honer Zu Siederdissen","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.transproceed.2017.12.012_bib22","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1097\/01.TP.0000053753.43268.F0","article-title":"Erosive enterocolitis in mycophenolate mofetil-treated renal-transplant recipients with persistent afebrile diarrhea","volume":"75","author":"Maes","year":"2003","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2017.12.012_bib23","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1016\/j.transproceed.2010.08.066","article-title":"Patterns of injury in mycophenolate mofetil-related colitis","volume":"42","author":"Al-Absi","year":"2010","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2017.12.012_bib24","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1136\/gut.2007.139972","article-title":"Crohn's-like enterocolitis associated with mycophenolic acid treatment","volume":"57","author":"Dost","year":"2008","journal-title":"Gut"},{"key":"10.1016\/j.transproceed.2017.12.012_bib25","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1097\/PAS.0b013e31816bf3fe","article-title":"Mycophenolate mofetil-related gastrointestinal mucosal injury: variable injury patterns, including graft-versus-host disease-like changes","volume":"32","author":"Parfitt","year":"2008","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.transproceed.2017.12.012_bib26","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.transproceed.2006.12.028","article-title":"Oral ulcers produced by mycophenolate mofetil in two liver transplant patients","volume":"39","author":"Naranjo","year":"2007","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2017.12.012_bib27","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/tri.12325","article-title":"Clinical significance of gastrointestinal bleeding after living donor liver transplantation","volume":"27","author":"Kimura","year":"2014","journal-title":"Transpl Int"},{"key":"10.1016\/j.transproceed.2017.12.012_bib28","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/00007890-199701150-00012","article-title":"Gastrointestinal bleeding after liver transplantation","volume":"63","author":"Tabasco-Minguillan","year":"1997","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2017.12.012_bib29","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1016\/j.transproceed.2008.07.017","article-title":"Fatal duodenal hemorrhage complicated after living donor liver transplantation: case report","volume":"40","author":"Lee","year":"2008","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2017.12.012_bib30","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1432-2277.1988.tb01818.x","article-title":"Prophylaxis with ranitidine against peptic ulcer disease after liver transplantation","volume":"1","author":"Klompmaker","year":"1988","journal-title":"Transpl Int"},{"key":"10.1016\/j.transproceed.2017.12.012_bib31","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1002\/hep.28782","article-title":"Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real-world cohort study","volume":"64","author":"Tapper","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.transproceed.2017.12.012_bib32","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/hep.28625","article-title":"Real-world effectiveness of ledipasvir\/sofosbuvir in 4,365 treatment-naive, genotype 1 hepatitis C-infected patients","volume":"64","author":"Backus","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.transproceed.2017.12.012_bib33","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1053\/j.gastro.2016.04.003","article-title":"Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens","volume":"151","author":"Pawlotsky","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.transproceed.2017.12.012_bib34","doi-asserted-by":"crossref","first-page":"432","DOI":"10.3350\/cmh.2016.0107","article-title":"Management of direct antiviral agent failures","volume":"22","author":"Buti","year":"2016","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.transproceed.2017.12.012_bib35","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jhep.2015.09.011","article-title":"The importance of resistance to direct antiviral drugs in HCV infection in clinical practice","volume":"64","author":"Sarrazin","year":"2016","journal-title":"J\u00a0Hepatol"}],"container-title":["Transplantation Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134517308680?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134517308680?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T11:33:55Z","timestamp":1635507235000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041134517308680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S0041134517308680"],"URL":"https:\/\/doi.org\/10.1016\/j.transproceed.2017.12.012","relation":{},"ISSN":["0041-1345"],"issn-type":[{"value":"0041-1345","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of Duodenal Ulcers due to the Discontinuation of Proton Pump Inhibitors After the Induction of Sofosbuvir Plus Ledipasvir Therapy: A Report of Two Cases","name":"articletitle","label":"Article Title"},{"value":"Transplantation Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transproceed.2017.12.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}